Skip to main content

Clinical trial LuMEn

The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours

Organ Multiple
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Oui
Sponsor Institut Jules Bordet
EudraCT Identifier 2012-00366-641
Inclusion criteria *Radiological progression RECIST 1.1 over the last 12 months*Disease progression on a PET/CT or SPECT/CT over the last 12 months*at least one lesion with hight tumour uptake on Ga-octreotate PET/CT and morphologically measurable according to RECIST1.1
Last update